Document is current
Any future updates will be listed below
-
Authors
Ykema, Matthew R.
Davis, Michael A.
Kasal, Darshan N.
Jennewein, Madeleine F.
Lo, Ethan https://orcid.org/0009-0007-0001-8787
Singh, Jasneet
Beaver, Samuel
Cross, Noah
Melief, Eduard https://orcid.org/0000-0002-2464-8966
Reed, Sierra
Press, Christopher
Brandt, Devin S.
McClary, Wynton D. https://orcid.org/0000-0003-3210-4747
Mohamath, Raodoh
Fusco, Pauline
Bakken, Julie
Casper, Corey
Hartwig, Airn Tolnay
Gerhardt, Alana
Bowen, Richard A.
Voigt, Emily A. https://orcid.org/0000-0001-5177-4063
- License Information
-
More Information
Article History
Received: 16 January 2025
Accepted: 26 September 2025
First Online: 13 January 2026
Competing interests
: A.G. and E.A.V. declare no Competing Non-Financial Interests but the following Competing Financial Interests. A.G. and E.A.V. are co-inventors on PCT patent application PCT/US21/40388, “Co-lyophilized RNA and Nanostructured Lipid Carrier,” and related national filings, as well as US provisional patent application 63/345,345, “Intranasal Administration of Thermostable RNA Vaccines,” and 63/144,169, “A thermostable, flexible RNA vaccine delivery platform for pandemic response.” All other authors declare that they have no competing interests.
